Table S3. A list of primers used in the reactions for real-time RT-PCR. (PDF 61Â kb
Primer pairs used for quantitative real-time PCR studies, including primer sequence, gene ID, and pr...
Table S1. Characteristics of the colorectal cancer patients analyzed in this study. Table S2. The pr...
Figure S1. Correlation of CYR61 expression of CRC tissues in IHC and clinicopathological parameters....
Table S1. The basic information of 8 colorectal cancer patients for TFAP2C mRNA and protein expressi...
Table S5. The relationship between TFAP2C IHC expression level and clinical. (PDF 61Â kb
Figure S1. TFAP2C expression level was elevated in colorectal cancer tissues compared with the benig...
Figure S4. Silencing TFAP2C inhibits proliferation ability of CRC cells. (A and B) Real-time PCR and...
Figure S9. (A and B) Analysis of ROCK1 and ROCK2 promoters physically associated with TFAP2C by usin...
Figure S2. Overexpression of TFAP2C is associated poor overall and progression-free survivals in CRC...
Figure S8. (A-B) The putative binding sites of TFAP2C in ROCK1 and ROCK2 promoters by JASPAR. (C and...
Figure S5. (A and B) Real-time PCR analysis of OCT4A, SOX2, NANOG and BMI-1 expression in the indica...
Figure S7. (A and B) Individual silencing of YAP or TAZ attenuated the sphere formation ability and ...
Figure S11. Clinical relation of TFAP2C with Hippo signaling activity in human CRC tissues. (A) Anal...
Figure S10. (A-D) The specific inhibitor of ROCK1 and ROCK2, Y-27632, significantly repressed SP fra...
Table S1. Primer sequences for the quantitative polymerase chain reaction. (DOC 76 kb
Primer pairs used for quantitative real-time PCR studies, including primer sequence, gene ID, and pr...
Table S1. Characteristics of the colorectal cancer patients analyzed in this study. Table S2. The pr...
Figure S1. Correlation of CYR61 expression of CRC tissues in IHC and clinicopathological parameters....
Table S1. The basic information of 8 colorectal cancer patients for TFAP2C mRNA and protein expressi...
Table S5. The relationship between TFAP2C IHC expression level and clinical. (PDF 61Â kb
Figure S1. TFAP2C expression level was elevated in colorectal cancer tissues compared with the benig...
Figure S4. Silencing TFAP2C inhibits proliferation ability of CRC cells. (A and B) Real-time PCR and...
Figure S9. (A and B) Analysis of ROCK1 and ROCK2 promoters physically associated with TFAP2C by usin...
Figure S2. Overexpression of TFAP2C is associated poor overall and progression-free survivals in CRC...
Figure S8. (A-B) The putative binding sites of TFAP2C in ROCK1 and ROCK2 promoters by JASPAR. (C and...
Figure S5. (A and B) Real-time PCR analysis of OCT4A, SOX2, NANOG and BMI-1 expression in the indica...
Figure S7. (A and B) Individual silencing of YAP or TAZ attenuated the sphere formation ability and ...
Figure S11. Clinical relation of TFAP2C with Hippo signaling activity in human CRC tissues. (A) Anal...
Figure S10. (A-D) The specific inhibitor of ROCK1 and ROCK2, Y-27632, significantly repressed SP fra...
Table S1. Primer sequences for the quantitative polymerase chain reaction. (DOC 76 kb
Primer pairs used for quantitative real-time PCR studies, including primer sequence, gene ID, and pr...
Table S1. Characteristics of the colorectal cancer patients analyzed in this study. Table S2. The pr...
Figure S1. Correlation of CYR61 expression of CRC tissues in IHC and clinicopathological parameters....
DOI
Add to ORKG